SCHEMBL4677419

SCHEMBL4677419

O=C(O)C(O)=CC(=O)c1cc(S(=O)(=O)c2ccc(F)cc2)n[nH]1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 7/20 0.47
CA12 O43570 1/20 0.38
ALPL P05186 1/20 0.38
RPA1 P27694 1/20 0.38
HTR2A P28223 2/20 0.36
KCNH2 Q12809 2/20 0.36
PTGS2 P35354 1/20 0.34
AKR1C2 P52895 1/20 0.34
AKR1C1 Q04828 1/20 0.34
AKR1C3 P42330 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HTR6 P50406 2/20 0.33
MAPT P10636 1/20 0.33
NAMPT P43490 1/20 0.33
CFTR P13569 1/20 0.33
KDM4E B2RXH2 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4675935 0.88 AKR1B1 (0.46) AKR1B1ALDH1A1HTR6MAPTNAMPT
SCHEMBL4674703 0.88 AKR1B1 (0.47) AKR1B1CA12ALPLAKR1C2AKR1C1
SCHEMBL4679011 0.81 AKR1B1 (0.41) AKR1B1CA12ALPLRPA1HTR2A
SCHEMBL4671350 0.77 MAPT (0.38) HTR2AKCNH2PTGS2AKR1C2AKR1C1
SCHEMBL4671347 0.77 MAPT (0.38) HTR2AKCNH2PTGS2AKR1C2AKR1C1
SCHEMBL4670742 0.75 PTGS2 (0.36) AKR1B1PTGS2AKR1C2AKR1C1AKR1C3
SCHEMBL4670745 0.75 PTGS2 (0.36) AKR1B1PTGS2AKR1C2AKR1C1AKR1C3
SCHEMBL4670604 0.73 CDK2 (0.39) AKR1B1HTR2AKCNH2PTGS2AKR1C2
SCHEMBL4671479 0.73 CA12 (0.39) CA12ALPLRPA1ALDH1A1MAPT
SCHEMBL4672206 0.73 MMP1 (0.39) HTR2AKCNH2PTGS2AKR1C2AKR1C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 AKR1B1 17/4885CA12 4245/4885ALPL 1995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.